- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp stock price live, this page displays NASDAQ ADPT stock exchange data. View the ADPT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Adaptive Biotechnologies Corp real time stock price chart below.
What Is the Adaptive Biotechnologies Corp Stock Price Today?
The Adaptive Biotechnologies Corp stock price today is 17.130.
What Is the Stock Symbol for Adaptive Biotechnologies Corp?
The stock symbol for Adaptive Biotechnologies Corp is ""ADPT.""
What Stock Exchange Does Adaptive Biotechnologies Corp Trade On?
Adaptive Biotechnologies Corp is listed and trades on the NASDAQ stock exchange.
Is Adaptive Biotechnologies Corp a Good Stock to Buy?
Determining whether Adaptive Biotechnologies Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADPT quote. (ISIN: US00650F1093)
What Is the Adaptive Biotechnologies Corp Stock Price Today?
The Adaptive Biotechnologies Corp stock price today is 17.130.
What Is the Stock Symbol for Adaptive Biotechnologies Corp?
The stock symbol for Adaptive Biotechnologies Corp is ""ADPT.""
What Stock Exchange Does Adaptive Biotechnologies Corp Trade On?
Adaptive Biotechnologies Corp is listed and trades on the NASDAQ stock exchange.
Is Adaptive Biotechnologies Corp a Good Stock to Buy?
Determining whether Adaptive Biotechnologies Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADPT quote. (ISIN: US00650F1093)
Fair Value
An estimate of a Adaptive Biotechnologies's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.500
18.870
52 wk Range
5.805
20.760
Unusual trading volume
1/2
Fair Value
An estimate of a Adaptive Biotechnologies's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.50018.870
52 wk Range
5.80520.760
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ADPT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Adaptive Biotechnologies's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
20.286
Upside
+18.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Adaptive Biotechnologies Corp Company Profile
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies Corp Earnings Call Summary for Q3/2025
- Adaptive Biotechnologies reported Q3 2025 EPS of $0.06 vs forecast of -$0.17, with revenue reaching $94M (up 102% YoY), exceeding expectations by 55.37%.
- MRD business achieved cash flow positivity, driving the company to raise full-year MRD revenue guidance to $202-207M with anticipated 104,000 tests for 2025.
- Adjusted EBITDA improved significantly to $28M from -$14.3M last year, with the company maintaining a strong cash position of $217M at quarter-end.
- Following earnings release, stock rose 3.96% to $16.92 and continues trading near its 52-week high of $17.89, reflecting strong investor confidence.
- CEO Chad Robins highlighted MRD as 'a profitable scaling business delivering consistent growth and margin expansion,' despite potential challenges from emerging competition.
Last Updated: 05/11/2025, 23:50
Read Full TranscriptCompare ADPT to Peers and Sector
Metrics to compare | ADPT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADPTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −32.8x | −3.6x | −0.6x | |
PEG Ratio | −0.54 | −0.01 | 0.00 | |
Price/Book | 12.8x | 2.3x | 2.6x | |
Price / LTM Sales | 10.3x | 4.7x | 3.3x | |
Upside (Analyst Target) | 18.1% | 9.9% | 41.4% | |
Fair Value Upside | Unlock | 6.3% | 6.0% | Unlock |
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 20.286
(+18.42% Upside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
0.06 / -0.17
Revenue / Forecast
93.97M / 60.48M
People Also Watch
FAQ
What Is the Adaptive Biotechnologies (ADPT) Premarket Price Today?
The Adaptive Biotechnologies (ADPT) premarket price is 18.650. Premarket price change units: -0.040. Premarket percentage change: -0.210%. Premarket volume: 4,760.000. Current date: 04 Dec 2025. Previous close: 18.690
What Stock Exchange Does Adaptive Biotechnologies Trade On?
Adaptive Biotechnologies is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Adaptive Biotechnologies?
The stock symbol for Adaptive Biotechnologies is "ADPT."
What Is the Adaptive Biotechnologies (ADPT) Afterhours Price Today? (Afterhours variable test: 17.450) Current Date: 04 Dec 2025
After hours price: 17.450. After hours price change (units): 0.320. Price change percentage: 1.870%
What Is the Adaptive Biotechnologies Market Cap?
As of today, Adaptive Biotechnologies market cap is 2.62B.
What Is Adaptive Biotechnologies's Earnings Per Share (TTM)?
The Adaptive Biotechnologies EPS (TTM) is -0.53.
When Is the Next Adaptive Biotechnologies Earnings Date?
Adaptive Biotechnologies will release its next earnings report on 16 Feb 2026.
From a Technical Analysis Perspective, Is ADPT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Adaptive Biotechnologies Stock Split?
Adaptive Biotechnologies has split 0 times.
How Many Employees Does Adaptive Biotechnologies Have?
Adaptive Biotechnologies has 619 employees.
What is the current trading status of Adaptive Biotechnologies (ADPT)?
As of 04 Dec 2025, Adaptive Biotechnologies (ADPT) is trading at a price of 17.130, with a previous close of 18.690. The stock has fluctuated within a day range of 16.500 to 18.870, while its 52-week range spans from 5.805 to 20.760.
What Is Adaptive Biotechnologies (ADPT) Price Target According to Analysts?
The average 12-month price target for Adaptive Biotechnologies is USD20.28571, with a high estimate of USD22 and a low estimate of USD18. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +18.42% Upside potential.
What Is the ADPT Premarket Price?
ADPT's last pre-market stock price is 18.650. The pre-market share volume is 4,760.000, and the stock has decreased by -0.040, or -0.210%.
What Is the ADPT After Hours Price?
ADPT's last after hours stock price is 17.450, the stock has decreased by 0.320, or 1.870%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.